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A CASE OF DRESS SYNDROME DUE TO VANCOMYCIN 
 
Danielle Zimmerman, M4, William Steinmann, MD 
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BACKGROUND 
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe systemic 
reaction that usually begins 2-6 weeks after the introduction of the inciting agent.  It is most 
commonly characterized by fever, rash, hematologic abnormalities (eosinophilia, atypical 
lymphocytosis), lymphadenopathy, HHV-6 reactivation and internal organ involvement. At least 10% 
of the cases are fatal. Treatment includes withdrawal of the offending medication and administration 
of corticosteroids, though the efficacy of the latter has not been fully evaluated. 
 
CASE REPORT 
A 64 year-old white male with past medical history of type 2 diabetes mellitus, hypertension, 
hyperlipidemia, COPD, coronary artery disease, gout, and a fifteen pack-year smoking history 
presented with complaints of fever, rash and abdominal discomfort. Patient developed a new pruritic, 
nontender rash on back, chest, arms associated with bilateral arm swelling and shortness of breath. 
Eight months prior to the admission, he had an open reduction for fracture of the left distal femur 
after a motor vehicle accident. He had two admissions related to this. One month previously, he was 
admitted with left septic knee, which was treated by arthrocentesis, screw removal, irrigation and 
drainage. Intravenous vancomycin was given and vancomyin beads were placed in the knee joint 
space.  Eight days prior to the arrival, the patient was readmitted with complaints of  fever, chills, left 
knee pain and the X-ray of the left knee was suggestive of  septic arthritis, which was  subsequently 
managed with irrigation and drainage. Vancomycin was continued and the patient was discharged two 
days prior to the current admission.  The patient hadn’t had any recent medication changes and 
denied any exposure to exotic pets, molds, dusts, chemicals, and drugs. 
 
On physical exam, his temperature was 37.8 °C with a blood pressure of 98/64mmHg. The exam 
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was remarkable for bilateral upper extremity edema and limited range of motion in the left knee 
secondary to mild swelling, without erythema or tenderness to palpation or movement. The skin  
exam revealed a very subtle, erythematous, papular, non-tender and non-confluent pruritic rash on 
chest and abdomen, more prominent on back and arms. Nikolsky sign was negative.  
            
            Figure A: Back showing rash with hyperemia and blanching; hospital day 6 
           Figure B: Edematous fingers and rash, left knee s/p ORIF in background; hospital day 6 
 
Laboratory results on admission revealed white blood cell count of 10,300/µL, with 16.5%
eosinophil’s (normal 0-10%), and platelet count of 390,000 /µL. Other labs included alkaline 
phosphatase of 332 U/L, AST of 225 U/L, and ALT of 413 U/L compared to previous normal LFT’s. 
Urinalysis was unremarkable and opacities, likely due to atelectasis. Peripheral smear from later 
hospital course showed large atypical eosinophil’s and no toxic granulations in neutrophils.  Blood 
culture remained negative during the hospital stay. Chest x-ray and abdominal ultrasound were 
unremarkable. 
 
Given the cutaneous changes, eosinophilia and other systemic signs, a presumptive diagnosis of 
DRESS syndrome was made.  Vancomycin was discontinued and patient was switchd to Daptomycin.   
Prednisone 60 mg daily was initiated for treatment of DRESS syndrome. The white counts increased 
to 18,800/µL on day 2, so steroids were held with concern regarding its immunosuppressive effects.   
Allopurinol was discontinued on hospital day 3, given its reported association with DRESS syndrome.  
However, as shown in the table over the next several days the white blood cell count escalated 
dramatically with accompanying eosinophilia. Without further signs of infection in the left knee, 
prednisone 60 mg was restarted on hospital day 7 to treat presumptive DRESS syndrome.   
 
The prednisone was tapered from 60mg to 30mg daily on hospital day 9. (The patient’s white cell 
count peaked at 44,000/µL on hospital day 10, and then decreased substantially by the day of 
discharge).  Improvement of the patient’s rash and edema was noted starting on hospital day 3 and 
continued until discharge, when the rash was no longer visible.  However, bilateral axillary 
lymphadenopathy persisted. (HHV-6 titer drawn on hospital day 2 were negative; however, a repeat 
HHV-6 titer drawn on hospital day 8 came back positive).  Due to absence of left shift and  
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toxic granulations in the neutrophils the infection and steroid response were less likely. Clonal 
hypereosinophilic disorder was also deemed unlikely because the eosinophils had been normal  
within the month.  Because  the patient continued to have complaints of left knee pain and given the 
leukocytosis, daptomycin was continued during this hospitalization.  Patient was discharged on 
Prednisone 30mg for total of ten days, and then tapered down to 10 mg every 10 days.    
 
DISCUSSION 
DRESS syndrome was originally identified as a hypersensitivity reaction to certain anticonvulsants, 
including carbamazepine, lamotrigine, and phenobarbital, but a number of other medications with 
aromatic groups have been reported to cause the syndrome (1, 2, 3, and 5), including about 18 cases 
reported with allopurinol and four with vancomycin (2).  Our patient had been on allopurinol for 
several years and he had started vancomycin about four weeks prior to the onset of symptoms, 
which makes vancomycin the most likely causative agent.  More support for this conclusion includes 
the score of 4 which is a “possible adverse drug reaction” according to Naranjo Adverse drug 
Reaction Scale (1) and a “definite” case of DRESS syndrome per the criteria described by Kardaun et. 
al (6).  Our patient also met all criteria for DRESS syndrome using the diagnostic criteria established 
by a Japanese consensus group (7). 
 
This case illustrates the challenge in making a definitive diagnosis of DRESS syndrome. As most of the 
clinical features of DRESS syndrome are non-specific, it may be difficult to exclude other conditions.  
In this case, our patient’s history of recent surgery and infection, leukocytosis, and leg pain made it 
difficult to rule out re-infection of the knee. Though infection of the knee remained a concern, 
DRESS syndrome was considered as highly probable because of the patient’s multiple negative blood 
cultures and absence of other signs of infection other than knee pain.  The most common 
manifestations of  DRESS syndrome include fever, rash, and systemic symptoms, including 
lymphadenopathy, leukocytosis, and organ damage. Our patient had elevated liver enzymes, axillary 
adenopathy and bilateral arm edema. 
 
Progression of WBC Count   
Date Hospital 
Day 
WBC X 103/ µL % Eosinophils Treatment Notes 
8/13 2 10.3 16 Daptomycin begun 
One dose prednisone given 
8/14 3 18.8 5 Daptomycin increased 
Allopurinol discontinued 
8/15 4 19.9 26   
8/16 5 22.7 20   
8/17 6 29.1 21   
8/18 7 29.9 18 Prednisone restarted 60 mg 
8/19 8 29.9 22 Prednisone 60 mg 
8/20 9 36.5 22 Prednisone 30 mg 
8/21 10 44.0 10 Prednisone 30 mg 
8/22 11 38.7 32 Prednisone 30 mg 
8/23 12 33.3 41 Prednisone 30 mg 
8/24 13 22.1 39 Prednisone 30 mg 
8/25 14 15.6 31 Prednisone 30 mg 
 The pathogenesis of DRESS syndrome is complex and has yet to be completely elucidated.  Both drug 
metabolism and genetic susceptibility have been implicated.  Hapten-carrier adduct formation, by 
either the drugs themselves or their metabolites, and nonconvalent drug presentation (8) may lead to 
T cell activation with an overrepresentation of CD8+ cells.  It has been hypothesized that the increased 
risk for DRESS syndrome and other drug reactions among patients with certain HLA variants is due to 
the affinity of certain drugs, their metabolites, or hapten-carrier adducts for specific HLA binding sites. 
 
These activated T cells produce the cytokines TNF α, IFN γ, and IL-2 that mediate the “cytokine 
storm,” which may be responsible for the wide constellation of symptoms seen in DRESS syndrome (8, 
9).  The expansion and activation of CD8+ cells may cause the reactivation of latent human herpes 
viruses seen at the onset of DRESS syndrome, typically HHV-6, but also HHV-7, CMV, EBV, and VZV 
(9).  The broad inflammatory response in DRESS syndrome encourages expansion of regulatory T cells, 
which are susceptible to infection by viruses such as HHV-6.  The infection and compromise of 
regulatory T cells may mediate the abnormal immunological function observed in this condition. While 
it has been proposed that polymorphisms in genes for detoxification enzymes may also contribute to 
DRESS syndrome by increasing the concentration of immunologically active or toxic metabolites, no 
such polymorphisms have yet been found (8). 
 
Detection of HHV-6 DNA and anti-HHV-6 IgG by PCR analysis is considered sensitive and specific for 
the diagnosis of DRESS syndrome outside of the United States (10).  Thymus and activation-regulated 
Chemokine (TARC/CCL17), a chemokine, has recently been proposed as an early marker for DRESS 
syndrome in a study of 29 patients, due to its role in TH2 type immunity (11). 
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RegiSCAR Diagnostic Criteria (6) 
 
Naranjo Adverse Drug Reaction Scale 
Hospitalization 
Reaction suspected to be drug-related 
Acute rash 
Fever > 38 °C* 
Enlarged lymph nodes at a minimum of two sites* 
Involvement of at least one internal organ* 
Blood count abnormalities* 
Lymphocytes above or below normal limits 
Eosinophils above the laboratory limits 
Platelets below the laboratory limits 
*3/4 of these are required to make the diagnosis 
1. Are there previous conclusive reports on this reaction? 
Yes (+1) No (0) Do not know or not done (0) 
2. Did the adverse event appear after the suspected drug was given? 
Yes (+2) No (-1) Do not know or not done (0) 
3. Did the adverse reaction improve when the drug was discontinued 
or a specific antagonist was given? 
Yes (+1) No (0) Do not know or not done (0) 
4. Did the adverse reaction appear when the drug was 
readministered? 
Yes (+2) No (-1) Do not know or not done (0) 
5. Are there alternative causes that could have caused the reaction? 
Yes (-1) No (+2) Do not know or not done (0) 
6. Did the reaction reappear when a placebo was given? 
Yes (-1) No (+1) Do not know or not done (0) 
7. Was the drug detected in any body fluid in toxic concentrations? 
Yes (+1) No (0) Do not know or not done (0) 
8. Was the reaction more severe when the dose was increased, or 
less severe when the dose was decreased? 
Yes (+1) No (0) Do not know or not done (0) 
9. Did the patient have a similar reaction to the same or similar drugs 
in any previous exposure? 
Yes (+1) No (0) Do not know or not done (0) 
10. Was the adverse event confirmed by any objective evidence? 
Yes (+1) No (0) Do not know or not done (0) 
Scoring 
> 9 = definite ADR 
5-8 = probable ADR 
1-4 = possible ADR 
0 = doubtful ADR 
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Current therapy is limited to withdrawal of the offending agent and initiation of corticosteroids to 
temper the immune response.  Our patient received oral prednisone, and the extreme leukocytosis 
began to subside four days after continuous therapy. Furthermore, his rash and edema had dissipated 
by the time of discharge.  However, it should be noted that there have been no controlled trials 
validating steroid therapy for this condition (1, 2, and 4).  There are several case reports of DRESS 
syndrome which showed improvement with IVIG, but given the expense and lack of evidence, it is  
used on an experimental basis only (12, 13).  While there are not yet any definitive indicators of 
mortality, a recent publication showed that an erythema multiforme-like rash, as opposed to the other 
cutaneous phenotypes possible with DRESS syndrome, may be prognostic for worse hepatic function 
during the course of illness (14).  Sequelae may include end-organ dysfunction (13) and autoimmune 
disease (15, 16). The latter may be due to viral reactivation and deregulated immune response (16). 
 
Physicians should maintain a low threshold of suspicion for DRESS syndrome when their patients 
present with a fever, rash, leukocytosis and eosinophilia and a history of new medication use.  Further 
study of documented cases of DRESS syndrome would be helpful in gaining a better understanding of 
the pathophysiology and optimal therapy for this potentially life threatening disorder.  
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ASK A PATHOLOGIST 
 
Emily Coberly, MD, Krystal Tray, MT, and William Miller, MD 
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QUESTION:  A 53 years old female receives transfusion of 2 units of PRBCs.  One hour later, she 
develops acute dyspnea with decreased O2 saturations.  Chest x-ray demonstrates new bilateral 
pulmonary infiltrates.  Could this patient have TRALI? 
 
ANSWER: Yes, Transfusion Related Acute Lung Injury (TRALI) is an uncommon but extremely 
serious complication of blood product transfusion.  It can occur with transfusion of any blood products 
that contains plasma, including RBCs, FFP, whole blood, platelets, and cryoprecipitate.  The risk of 
TRALI is estimated to be between1:2000 and 1:5000 units of blood products; and TRALI is the leading 
cause of transfusion-related mortality. 
 
TRALI is most commonly caused by donor plasma containing anti-leukocyte antibodies, which react 
with neutrophils in the pulmonary micro-vasculature of the recipient, leading to increased vascular 
permeability and a pulmonary capillary leak syndrome resembling ARDS. 
 
By definition, TRALI occurs during or within 6 hours of transfusion of a plasma-containing blood 
product.  Symptoms include sudden onset of respiratory distress with clinical and x-ray evidence of 
acute bilateral pulmonary edema.  Hypotension and fever are often present.  TRALI is a diagnosis of 
exclusion and must be distinguished from the more common Transfusion Associated Circulatory 
Overload (TACO).  BNP and NT-pro-BNP levels can be elevated in both conditions and do not 
reliably distinguish between the two diagnoses.  As opposed to TACO, TRALI does not respond to 
diuretics.  Treatment of TRALI is supportive; symptoms typically resolve within 72 hours.   Mortality is 
5-10%. 
 
If you suspect a patient may have TRALI, it is extremely important to contact your pathologist or 
blood bank immediately.  Since TRALI is often caused by antibodies in donor plasma, the blood donor 
center must be contacted to quarantine any remaining products from the suspect donors.  Suspect 
donors are tested for anti-leukocyte antibodies, and donors implicated in an episode of TRALI are 
evaluated for continued eligibility to donate blood products. 
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